MedTrace Logo

Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

NCT06513949 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2025-08-20

No results posted yet for this study

Summary

Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days.

The primary outcome is the day 4 oxygenation index assessed as a continuous measure.

Conditions

  • Acute Respiratory Distress Syndrome
  • Adult Respiratory Distress Syndrome
  • Acute Lung Injury
  • Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

Interventions

BIOLOGICAL

Atibuclimab

monoclonal antibody against human CD14

OTHER

Placebo

Sterile normal saline for injection

Sponsors & Collaborators

Principal Investigators

  • Linzee Mabrey, MD, MsC · Unversity of Washington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-15
Primary Completion
2027-09-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06513949 on ClinicalTrials.gov